Zevra Therapeutics (ZVRA) Receivables (2018 - 2025)
Historic Receivables for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to $16.8 million.
- Zevra Therapeutics' Receivables rose 11618.74% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 11618.74%. This contributed to the annual value of $10.8 million for FY2024, which is 4181.92% down from last year.
- Zevra Therapeutics' Receivables amounted to $16.8 million in Q3 2025, which was up 11618.74% from $18.3 million recorded in Q2 2025.
- Over the past 5 years, Zevra Therapeutics' Receivables peaked at $18.6 million during Q4 2023, and registered a low of $1.6 million during Q4 2021.
- Its 5-year average for Receivables is $9.2 million, with a median of $8.9 million in 2024.
- Data for Zevra Therapeutics' Receivables shows a peak YoY increase of 47571.87% (in 2022) and a maximum YoY decrease of 7164.33% (in 2022) over the last 5 years.
- Quarter analysis of 5 years shows Zevra Therapeutics' Receivables stood at $1.6 million in 2021, then surged by 475.72% to $9.4 million in 2022, then soared by 97.97% to $18.6 million in 2023, then crashed by 41.82% to $10.8 million in 2024, then surged by 55.33% to $16.8 million in 2025.
- Its last three reported values are $16.8 million in Q3 2025, $18.3 million for Q2 2025, and $12.6 million during Q1 2025.